Basilea Pharmaceutica AG Stock
Stocks
BSLN
CH0011432447
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Swiss Exchange
11:31:41 2026-10-16 EDT
|
5-day change | 1st Jan Change | ||
| 65.60 CHF | -4.37% |
|
+0.15% | +19.93% |
| 09-14 | Japanese Stocks Fall on AI Development Slowdown Calls; Oil Gains | MT |
| 09-14 | Asahi Kasei Unit Starts Phase Two Study of Antifungal Cresemba for Pediatric Patients in Japan | MT |
| Market Cap | 815M 989M 879M 741M 1.4B 93.86B 1.42B 9.79B 3.84B 48.98B 3.71B 3.63B 156B | P/E 2026 * |
15.2x | P/E 2027 * | 17x |
|---|---|---|---|---|---|
| Enterprise Value | 662M 804M 714M 602M 1.14B 76.27B 1.15B 7.96B 3.12B 39.8B 3.02B 2.95B 127B | EV / Sales 2026 * |
2.47x | EV / Sales 2027 * | 2.17x |
| Free-Float |
91.74% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Swiss Exchange
| BSLN | Delayed | |
London S.E.
| 0QNA | Delayed | |
|
CBOE
| 0QNA | Real-time | |
|
Tradegate
| PK5 | Real-time | |
|
OTC Markets
| BPMUF | Delayed | |
|
Boerse Muenchen
| PK5 | Real-time | |
|
Deutsche Boerse AG
| PK5 | Delayed | |
|
Börse Stuttgart
| PK5 | Delayed |
Last Transcript: Basilea Pharmaceutica AG
| 1 day | -4.37% | ||
| 1 week | +0.15% | ||
| Current month | -6.15% | ||
| 1 month | -1.35% | ||
| 3 months | +26.64% | ||
| 6 months | +19.06% | ||
| Current year | +19.93% |
| 1 week | 64.4 |  | 68.7 |
| 1 month | 64.1 | | 70.5 |
| Current year | 47.8 | | 70.5 |
| 1 year | 44.7 | | 70.5 |
| 3 years | 32 | | 70.5 |
| 5 years | 29.55 | | 70.5 |
| 10 years | 29.28 | | 95.35 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Veitch
CEO | Chief Executive Officer | 61 | 2018-04-18 |
Adesh Kaul
DFI | Director of Finance/CFO | 52 | 2019-04-09 |
Gerrit Hauck
CTO | Chief Tech/Sci/R&D Officer | 62 | 2018-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Thomas Werner
BRD | Director/Board Member | 70 | 2011-11-28 |
| Chairman | 71 | 2013-04-08 | |
Nicole Onetto
BRD | Director/Board Member | 73 | 2017-04-26 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 5/29/26 | Sell | -400 | 0.0030% | |||
| 5/13/26 | Sell | -1,043 | 0.0078% | |||
| 5/4/26 | Sell | 400 | 0.0030% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.37% | +0.15% | +34.15% | +69.73% | 989M | |
| -6.60% | -8.56% | +42.79% | +64.16% | 65B | |
| -4.09% | -0.11% | +2.31% | +54.81% | 51.19B | |
| +0.03% | +5.56% | +10.18% | +41.75% | 51.2B | |
| -1.53% | +2.70% | +29.72% | +34.13% | 43.93B | |
| -1.34% | +4.12% | +16.05% | +112.18% | 41.96B | |
| -5.97% | -6.22% | +258.21% | +421.57% | 38.14B | |
| +6.53% | +8.02% | +15.74% | +53.94% | 33.24B | |
| -0.90% | -10.49% | +31.48% | -1.63% | 25.2B | |
| -2.76% | -9.54% | -16.53% | -9.55% | 22.03B | |
| Average | -2.10% | -1.49% | +42.41% | +84.11% | 37.29B | |
| Weighted average by Cap. | -2.30% | -1.20% | +43.54% | +88.53% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 268M 325M 289M 244M 460M 30.86B 467M 3.22B 1.26B 16.11B 1.22B 1.19B 51.34B | 275M 334M 297M 250M 472M 31.7B 480M 3.31B 1.3B 16.54B 1.25B 1.23B 52.73B |
| Net income | 68.7M 83.38M 74.12M 62.5M 118M 7.91B 120M 826M 324M 4.13B 313M 306M 13.16B | 58.3M 70.76M 62.9M 53.04M 100M 6.72B 102M 701M 275M 3.5B 266M 260M 11.17B |
| Net Debt | -153M -185M -165M -139M -262M -17.59B -266M -1.84B -720M -9.18B -696M -681M -29.26B | -218M -264M -235M -198M -374M -25.1B -380M -2.62B -1.03B -13.1B -993M -971M -41.75B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-16 | CHF 65.60 | -4.37% | 25,814 |
| 26-10-15 | CHF 68.60 | +3.16% | 43,629 |
| 26-10-14 | CHF 66.50 | +2.78% | 26,544 |
| 26-10-13 | CHF 64.70 | -1.52% | 15,702 |
| 26-10-12 | CHF 65.70 | +0.31% | 17,344 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BSLN Stock
Select your edition
All financial news and data tailored to specific country editions
